ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 906,58
-0,27%
Dow Jones
44 713,58
0,65%
DAX
21 282,18
-0,48%
Brent Oil
76,445
0,23%
Bitcoin
102 812,98
0,73%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Design Therapeutics Inc (DSGN) Cours

Design Therapeutics Inc

Design Therapeutics Inc (DSGN)

NASDAQ
5,06
0,09
(1,81%)
Fermé 28 Janvier 10:00PM
Retardé de 15 minutes
5,06
0,01
(0,20%)
Après les heures de négociation: 10:52PM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
5,06
Prix Achat
4,63
Prix Vente
5,06
Volume échangé
121 503
4,77 Fourchette du Jour 5,18
2,245 Plage de 52 semaines 7,77
Cap du marché
286,502M
Clôture Veille
4,97
Ouverture
4,77
Dernière Transaction
2
@
5.06
Dernière heure de transaction
Volume financier
US$ 609 924
VWAP
5,0198
Volume moyen (3 m)
191 887
Actions en circulation
56 621 037
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,28
Bénéfice par action (BPA)
-1,18
Chiffre d'affairess
-
Bénéfice net
-66,86M

À propos de Design Therapeutics Inc

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.designtx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Design Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker DSGN. Le dernier cours de clôture d'Design Therapeutics était de US$4,97. Au cours de la dernière année, les actions de Design Therapeutics ont été négociées dans une fourchette de prix de US$ 2,245 à US$ 7,77.

Design Therapeutics compte actuellement 56 621 037 actions en circulation. La capitalisation boursière d'Design Therapeutics est de US$281,41 million. Design Therapeutics a un ratio cours/bénéfice (ratio PE) de -4.28.

DSGN Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

20 Décembre 2024
Edgar (US Regulatory)

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic...

13 Novembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

07 Novembre 2024
Edgar (US Regulatory)

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose...

07 Novembre 2024
GlobeNewswire Inc.

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...

10 Septembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

12 Août 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

09 Août 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.09-1.747572815535.155.2654.81841335.01404558CS
4-1.13-18.25525040396.196.813.712161955.06709638CS
12-0.09-1.747572815535.157.773.711918875.84465416CS
26-0.11-2.127659574475.177.773.712244265.46936489CS
522.71115.3191489362.357.772.2452310514.54005689CS
156-7.12-58.456486042712.1826.31.943488196.84013635CS
260-22.94-81.928571428628501.943050728.3758143CS

DSGN - Frequently Asked Questions (FAQ)

What is the current Design Therapeutics share price?
The current share price of Design Therapeutics is US$ 5,06
How many Design Therapeutics shares are in issue?
Design Therapeutics has 56 621 037 shares in issue
What is the market cap of Design Therapeutics?
The market capitalisation of Design Therapeutics is USD 281,41M
What is the 1 year trading range for Design Therapeutics share price?
Design Therapeutics has traded in the range of US$ 2,245 to US$ 7,77 during the past year
What is the PE ratio of Design Therapeutics?
The price to earnings ratio of Design Therapeutics is -4,28
What is the reporting currency for Design Therapeutics?
Design Therapeutics reports financial results in USD
What is the latest annual profit for Design Therapeutics?
The latest annual profit of Design Therapeutics is USD -66,86M
What is the registered address of Design Therapeutics?
The registered address for Design Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Design Therapeutics website address?
The website address for Design Therapeutics is www.designtx.com
Which industry sector does Design Therapeutics operate in?
Design Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
JGAurora Mobile Ltd
US$ 14,56
(142,18%)
38,51M
AKROAkero Therapeutics Inc
US$ 51,77
(97,75%)
15,06M
ORKTOrangeKloud Technology Inc
US$ 1,30
(88,41%)
62,83M
HWHHWH International Inc
US$ 0,49
(70,32%)
393,88M
GITSGlobal Interactive Technologies Inc
US$ 3,0424
(56,34%)
4,71M
ALLKAllakos Inc
US$ 0,2402
(-80,15%)
51,22M
NXUNXU Inc
US$ 0,2513
(-59,20%)
14,06M
VERUVeru Inc
US$ 0,6351
(-47,51%)
43,51M
WOKWORK Medical Technology Group Ltd
US$ 2,53
(-47,51%)
862,6k
NBISNebius Group NV
US$ 26,08
(-37,44%)
43,58M
NVDANVIDIA Corporation
US$ 118,42
(-16,97%)
798,94M
HWHHWH International Inc
US$ 0,49
(70,32%)
393,88M
HOLOMicroCloud Hologram Inc
US$ 1,67
(7,74%)
201,58M
ONCOOnconetix Inc
US$ 0,66
(37,50%)
185M
RGTIRigetti Computing Inc
US$ 12,44
(-5,76%)
123,5M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
DSGN
Design Therapeutics
BIT
NSCIT5399588
Cassa Depositi e Prestit...
BIT
I10197
XS2858864908 20310910 16...
BIT
P1DD87
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés